These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659 [TBL] [Abstract][Full Text] [Related]
15. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051 [TBL] [Abstract][Full Text] [Related]
16. The value of ultrasonography for the indication of fine-needle aspiration in autonomous thyroid nodules. Rosario PW; de Castro Nicolau T Diagn Cytopathol; 2021 Mar; 49(3):363-366. PubMed ID: 33152168 [TBL] [Abstract][Full Text] [Related]
17. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Kim SK; Kim DL; Han HS; Kim WS; Kim SJ; Moon WJ; Oh SY; Hwang TS Diagn Mol Pathol; 2008 Jun; 17(2):118-25. PubMed ID: 18382358 [TBL] [Abstract][Full Text] [Related]
18. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice. Witt RL Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717 [TBL] [Abstract][Full Text] [Related]
19. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes. Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275 [TBL] [Abstract][Full Text] [Related]